Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2014

Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 2014;4(3):318-33.

Yang GC, Kuhel WI, Scognamiglio T. Amyloid-rich low grade adenocarcinoma of the parotid: fine-needle aspiration cytology with histologic correlations. Diagn Cytopathol. 2014;42(9):798-801.

Gupta A, Hunt CR, Hegde ML, Chakraborty S, Chakraborty S, Udayakumar D, et al. MOF phosphorylation by ATM regulates 53BP1-mediated double-strand break repair pathway choice. Cell Rep. 2014;8(1):177-89.

Westblade LF, Haghi N, Pritt BS, Edelman M. Photo Quiz. Appendicitis in a 4-year-old child. Clin Infect Dis. 2014;58(3):400, 442-3.

Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature. 2014;508(7494):103-107.

Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, et al. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(10):2027-31.

Magro CM, Wang X, Subramaniyam S, Darras N, Mathew S. Cutaneous double-hit B-cell lymphoma: an aggressive form of B-cell lymphoma with a propensity for cutaneous dissemination. Am J Dermatopathol. 2014;36(4):303-10.

Ogunrinade O, Ahn CS, Gergis U, Yassin AH, Magro C. Cutaneous lymphocyte antigen expression loss and PD1 positivity in early cutaneous lesions of rapidly progressive mycosis fungoides. Clin Case Rep. 2014;2(5):209-18.

Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, et al. Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev. 2014;23(4):594-600.

Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645-51.